whereas in controls it occurred 20 min after the start of randomized to receive intravenous infusion of GTN infusion. The present study demonstrates that an NO-(0.5 µg/kg per minute for 20 min) or placebo on two induced biphasic response with an immediate and a headache-free days separated by at least 1 week. Headache delayed headache is common to chronic tension-type intensity was measured on a 10-point verbal rating scale headache and migraine. Furthermore, the NO-induced during 2 h of observation and for the next 10 h after delayed headache has the characteristics of the primary discharge from hospital. The primary endpoints were the headache disorder. This suggests that NO contributes to difference between the area under the curve (AUCthe mechanisms of several types of primary headaches intensities ⍥ duration) for headache recorded on the day and that NO-related central sensitization may be an of GTN treatment and on the day of placebo treatment important common denominator in the pain mechanisms of primary headaches. in patients, and in patients and controls on the days of
Introduction
Nitric oxide (NO) plays a key role in migraine (Thomsen unknown, however, whether NO induces more intense headache in patients with chronic tension-type headache than and Olesen, 1998) and cluster headache (Fanciullacci et al., in healthy controls and, if so, what the characteristics and 1997). This freely diffusible molecule is involved in a time profile of such headache might be. In the present study variety of biological functions, including neurotransmission we recorded the intensity, quality and time profile of headache (Garthwaite and Boulton, 1995) . NO also contributes to after infusion of the NO donor GTN in patients with chronic sensory transmission in the peripheral and central nervous tension-type headache and compared GTN-induced headache system (Aley et al., 1998; Wu et al., 1998) . We have observed in patients and healthy controls. previously that systemic administration of the NO donor glyceryl trinitrate (GTN) may induce strong immediate headache in patients with episodic tension-type headache
Material and methods
compared with healthy subjects (Olesen et al., 1993) , and we demonstrated recently that nitric oxide synthase (NOS) Subjects inhibition has an analgesic effect in patients with chronic
We recruited 16 patients with a diagnosis of chronic tensiontype headache according to the criteria of the International tension-type headache (Ashina et al., 1999) . It remains Headache Society (IHS) (Headache Classification Committee, measurement has been used in previous studies of GTN-1988) (headache frequency ജ15 days per month for ജ6 induced headache in migraineurs (Thomsen et al., 1994) . months) from the out-patient headache clinic at Glostrup Twelve-lead ECG was performed before examination. Any Hospital (Table 1 ). All patients underwent a general physical adverse events were recorded. Subjects with headache examination and a neurological examination and completed 120 min after the start of infusion were allowed to take a diagnostic headache diary (Russell et al., 1992 ) during a rescue medication. All subjects were asked to record details 4-week run-in period. Exclusion criteria were: history of of the following on a diary card 4, 8, 12, 16, 20 and 24 h migraine or any other type of primary headaches; any kind after start of infusion: headache location; headache intensity of daily medication (including prophylactic headache therapy (verbal rating scale); headache quality and aggravation by but not oral contraceptives); excessive use of analgesics physical activity; associated symptoms; any medication taken; (corresponding to Ͼ2 g aspirin/day); serious somatic or and adverse events. The diary cards were mailed to the clinic psychiatric diseases, including depression (Hamilton after each treatment. depression score ജ17) (Hamilton, 1960) .
Sixteen healthy volunteers served as controls (Table 1 ). The controls never had migraine and had fewer than 12
Data analysis and statistics
headache days per year.
Results are presented as median with quartiles in parentheses. All subjects gave written consent to participation in the The primary endpoint was the difference between the area study, which was approved by the local ethics committee under the headache curve (AUC-intensity ϫ duration) and conducted in accordance with the Declaration of Helsinki.
recorded over 12 h of observation on an active day and on a placebo day in patients. The secondary endpoint was the difference between the AUC recorded on the active day in patients and controls. The AUC was calculated according to Procedures the trapezium rule (Matthews et al., 1990) . The difference In a double-blind, placebo-controlled crossover design, the between the AUCs recorded on an active day and on a patients and controls were allocated randomly to receive placebo day within patients and controls was compared by GTN at 0.5 µg/kg per minute or placebo (isotonic saline) on the use of the Wilcoxon signed ranks test. The difference 2 days separated by at least 1 week. Medical staff not between the AUCs recorded on an active day in patients and involved in the study performed the randomization and controls was compared by the use of the Mann-Whitney test. prepared the study drug. The randomization code remained To assess changes in blood pressure and pulse rate in patients in the hospital during the study and was not available to the over the first 60 min after active treatment or placebo, we investigators until the study was complete. All subjects, who used the paired samples t-test. Five per cent was accepted as had been completely headache-free for at least 12 h before the level of significance. All data were analysed with SPSS ® the examination, were examined on days without headache version 7.5.1 software (SPSS Inc., Chicago, Ill., USA). at 09.00 hours. The subjects were not allowed to take any kind of analgesic for 24 h before the examination. GTN or placebo was infused over 20 min into an antecubital vein, as allocated by the randomization code. The study solutions 
GTN and placebo infusions in patients
at baseline and every 5 min until 60 min after the start of The AUC on a GTN day [2221 (1572-3704)] , was infusion and then every 15 min until 120 min after the start significantly higher than on a placebo day [730 (60-1678)] of infusion: headache intensity on a verbal rating scale (P ϭ 0.008) (Fig. 1) . During GTN infusion, 15 out of 16 (0-10: 0, no headache; 5, moderate headache; 10, worst patients developed immediate headache, with peak intensity imaginable headache); blood pressure and pulse rate. The verbal rating scale was chosen because this method of pain 20 min after the start of infusion (Table 2 and Fig. 1 ). One Median headache intensity during (20 min) and after infusion of GTN and placebo in 16 patients with chronic tension-type headache. Headache was scored on a 10-point verbal rating scale (VRS). The area under the headache curve (intensity ϫ duration) on a GTN day (filled squares) was significantly higher than on a placebo day (open squares) (P ϭ 0.008). The headache intensity reached its peak value 8 h after the start of the GTN infusion and was higher than after placebo.
patient (patient 16) developed a migraine-like headache

GTN infusion in patients versus controls
lasting~15 min (Table 2) . During placebo infusion, three out The AUC in patients [2221 (1572-3704)] was significantly of 16 patients developed a bilateral, mild (range 2-3 on the higher than that in controls [43 (0-972)] (P ϭ 0.0001). verbal rating scale), pressing headache without associated symptoms. After GTN infusion, 15 out of 16 patients developed a delayed headache (Table 2 ) with peak intensity
GTN infusion in patients with pressing
8 h after the start of infusion (Fig. 1 ). In 13 patients the headache versus controls headache fulfilled IHS criteria for tension-type headache, When the five patients whose usual headache quality was while two patients (patients 14 and 15) developed a headache throbbing were excluded, the remaining 11 patients, whose which fulfilled the diagnostic criteria for migraine without headache was of a pressing quality, still had a significantly aura. Eight patients took simple analgesics as a rescue higher response to GTN [2003 GTN [ (1410 GTN [ -2873 ] than 16 controls medication on the GTN day. After placebo infusion, 11
[43 (0-972)] (P ϭ 0.0001). In these patients, the AUC on patients reported a delayed headache. The headache intensity the GTN day [2003 (1410-2873) ] was also significantly of these patients reached its peak 10 h after the start of higher than on a placebo day [660 (0-1348)] (P ϭ 0.02). infusion (Fig. 1) . None of the patients developed a migraine None of these patients developed a migraine headache. headache. Two patients took simple analgesics as a rescue medication on the placebo day.
Immediate and delayed headache in patients GTN and placebo infusions in controls
The AUC recorded over the initial 120 min (immediate The AUC on the GTN day [43 (0-972)] was significantly headache) observation on the GTN day [171 (31-426)] was higher than on the placebo day [0 (0-0)] (P ϭ 0.008) (Fig. 2) . significantly higher than on the placebo day [0 (0-91)] (P ϭ During the GTN infusion, nine out of 16 controls developed 0.02). The AUC recorded from 120 min to 12 h (delayed a headache without associated symptoms. The headache headache) after infusion on the GTN day [2108 (1541-3465)] intensity reached its peak 20 min after the start of infusion.
was significantly higher than on the placebo day [720 (60-After discharge from hospital, six out of 16 controls developed 1410)] (P ϭ 0.008). a delayed headache (Table 3) . One subject (subject 3) developed a headache, which fulfilled the IHS diagnostic
Haemodynamics in patients
criteria for migraine without aura. On the placebo day, none
The mean arterial blood pressure (MAP) decreased of the subjects developed a headache during the infusion or in the 12 h following infusion.
significantly during treatment with GTN compared with a ϭ usual headache; b ϭ headache during GNT infusion (20 min); c ϭ peak headache after glyceryl trinitrate infusion; sev. ϭ severe; mod. ϭ moderate; pres. ϭ pressing; throb. ϭ throbbing; -ϭ not applicable. *Time to postinfusion peak; † headache aggravation by physical activity; ‡ fulfilling IHS criteria for migraine without aura; § intake and time of intake of rescue medication.
placebo (P ϭ 0.01) (Fig. 3 ). Patients were clinically pulse rate during treatment with GTN and placebo (P ϭ 0.50) (Fig. 3) . unaffected by these changes. There was no difference in The area under the curve on a GTN day (circles) was significantly higher than on a placebo day (sunbursts) (P ϭ 0.008). 
Previous studies of experimental headache in tension-type headache
In 1980, Krabbe and Olesen infused histamine intravenously
Present results in relation to findings in
into patients with chronic tension-type headache (Krabbe and Olesen, 1980) . The patients developed pressure-like, constant
migraine
It was important to compare the GTN response with the headache with an intensity intermediate between those in migraine patients and healthy controls. It was not reported placebo response in patients with chronic tension-type headache, because a high proportion of these patients were whether the patients developed delayed headache. Histamine presumably causes production of NO via an endothelial H 1 expected to develop their usual headache in the experimental period. In the present study, 15 out of 16 patients developed receptor (Lassen et al., 1996) . In another study, by Olesen and colleagues, the exogenous NO donor GTN was given a delayed headache with mean peak intensity 8 h after the start of GTN infusion. Eleven patients developed a delayed intravenously to 17 migraineurs, nine patients with episodic tension-type headache and 17 healthy control subjects (Olesen headache of low intensity with a maximum 10 h after placebo infusion. This was likely to represent their usual headache. et al., 1993) . Seven out of nine patients developed a nitroglycerin-induced headache (immediate) with intensity Both the immediate (0-2 h observation) and the delayed (2- Fig. 3 Changes in mean arterial blood pressure (MAP) and pulse rate during and after infusion of GTN and placebo in patients with chronic tension-type headache. The MAP decreased significantly during treatment with GTN (filled squares) compared with placebo (open squares) (P ϭ 0.01). The peak decrease in MAP was 11 Ϯ 2% (mean Ϯ SEM) and occurred 15 min after the start of GTN infusion. There was little difference in pulse rate during treatment with GTN (circles) and placebo (sunbursts) (P ϭ 0.50). The maximum increase in pulse rate was 20 Ϯ 6% (mean Ϯ SEM) and occurred 10 min after the start of GTN infusion. The plots show mean scores.
12 h observation) headache were significantly stronger on Our results indicate that patients with chronic tension-type headache similar to that of patients with migraine are the GTN day than on the placebo day. In controls, GTN induced a headache during infusion, which rapidly supersensitive to NO, and that the majority of patients in both groups develop their usual headache several hours after disappeared after the infusion had stopped. Interestingly, the time profile of the GTN-induced headache in patients with the infusion of GTN. chronic tension-type headache was strikingly similar to the time profile of GTN-induced headache in patients with migraine without aura (Thomsen et al., 1994) . Thus, patients
Possible mechanisms of immediate and delayed
with migraine without aura developed an immediate headache during GTN infusion and a delayed headache fulfilling the headache The most important finding in the present study was that IHS criteria for migraine several hours after the infusion was stopped. Peak intensity occurred 5.5 h after the infusion was systemic administration of the NO donor GTN in patients with chronic tension-type headache, as in migraineurs, resulted in stopped. The characteristics of the delayed headache in chronic tension-type headache were, however, different from a biphasic nociceptive response with a headache peak during infusion (immediate headache), a reduction in headache those in patients with migraine. Thus, 80% of migraine patients developed migraine without aura after infusion of intensity for~1.5 h (intermediate phase), and a second and more pronounced headache peak several hours later (delayed GTN (Thomsen et al., 1994) , whereas only 13% of patients with chronic tension-type headache did so in the present headache). We suggest that a direct effect of NO on perivascular sensory afferents and/or NO-induced arterial study. The other 87% developed a tension-type headache. None of our patients had previously experienced migraine dilatation are responsible for the immediate headache and that enhanced central sensitization at the spinal/trigeminal fulfilling the IHS criteria. To exclude the possibility that previous migraine had been overlooked, patients who had level is responsible for the delayed headache. NO evokes pain in humans when injected paravascularly previously experienced throbbing headaches were analysed separately. Two patients who developed migraine headache or perfused through a vascularly isolated segment of a hand vein (Holthusen and Arndt, 1995) . These findings suggest were in this group, but the three others did not develop migraine. Furthermore, patients with exclusively pressing that NO may directly activate or sensitize nociceptors around blood vessels. Intravenous infusion of GTN (0.5 µg/kg per pain in the past also developed a significantly stronger headache during and after GTN infusion than controls. minute) over 20 min induces dilatation of the middle cerebral artery in healthy subjects (Iversen et al., 1989) and in in the CNS, thereby increasing the sensitization of nociceptive pathways in the CNS. migraineurs and patients with episodic tension-type headache Sustained NO-induced vascular nociception may lead to (Thomsen et al., 1993) . In these studies the dilatation lasted central sensitization and the subsequent convergence of at least until 1 h after GTN infusion had stopped (Iversen nociceptive input from blood vessels and myofascial tissue. et al., 1989; Thomsen et al., 1993) and 3 h in another study
As mentioned earlier, NO may activate or sensitize (Lassen et al., 1996) . Furthermore, vasodilatation of the nociceptors around blood vessels directly or by dilatation. middle meningeal artery in rats increases the firing rate in Dilatation of the meningeal blood vessels in rats causes the trigeminal nucleus caudalis (Cumberbatch et al., 1999) .
sensitization of central trigeminal neurones and facilitation Collectively, these studies suggest that immediate headache of convergent sensory responses (Cumberbatch et al., 1999) . after infusion of GTN in patients with chronic tensionInterestingly, trigeminal neurones became maximally type headache may originate in NO-induced activation or sensitized after the peak increase in vessel diameter and the sensitization of sensory nerves around the cephalic/ increased excitability exceeded the period of vasodilatation extracephalic arteries or from NO-induced arterial dilatation, (Cumberbatch et al., 1999) . It is, therefore, possible that or both.
excessive vascular nociception caused by GTN may gradually Basic pain research has demonstrated that central augment the sensitizing effect of pre-existing myofascial input sensitization, i.e. increased excitability of neurones in the in chronic tension-type headache sufferers (Olesen, 1991) . CNS, generated by prolonged nociceptive input from the The questions of why patients with chronic tensionperiphery, plays an important role in the pathophysiology of type headache and patients with migraine develop delayed chronic pain (Woolf, 1983; Hu et al., 1992; Woolf and headache of greater intensity with different characteristics Doubell, 1994) . NO is released in the spinal cord during and why most healthy subjects develop no delayed headache central sensitization, and prolonged elevation of NO within or only a minor one are important. The most likely explanation the spinal dorsal horn is important in maintaining the central is that pre-existing facilitation of distinct nociceptive central sensitization (Lin et al., 1999) . While inhibition of NOS has pathways in chronic tension-type headache sufferers been shown to reduce central sensitization in animal models (myofascial pathways) and migraineurs (vascular pathways) of persistent pain (Haley et al., 1992; Hao and Xu, 1996;  may be enhanced by NO-induced central sensitization. This Mao et al., 1997) , nociceptive responses in these models are could explain why the delayed headache fulfilled tensionenhanced by NO donors (Kitto et al., 1992; Coderre and type headache criteria in patients with chronic tension-type Yashpal, 1994). Furthermore, it was reported that inhibition headache and migraine criteria in migraineurs. This could of NOS markedly reduces Fos expression in the also explain why NO does not induce strong delayed headache trigeminocervical complex of the cat after stimulation of the in healthy subjects when no pre-existing sensitization is superior sagittal sinus (Hoskin et al., 1999) . Interestingly, in present. animals, formalin-induced tissue injury results in a biphasic
In conclusion, the present study provides important nociceptive response (Coderre and Yashpal, 1994) similar to information about NO mechanisms in chronic tension-type that observed in the present study. The second pain phase headache. It is suggested that NO-induced delayed headache may be caused by central sensitization, and NOS inhibition in patients with chronic tension-type headache is due to reduces pain only in this phase (Coderre and Yashpal, 1994) . augmentation of pre-existing central sensitization. Moreover, Recent clinical studies suggest that central sensitization at our results indicate that NO contributes to the mechanisms the spinal/trigeminal level caused by nociceptive input from of several types of primary headaches and that NO-related pericranial myofascial tissues may play an important role in central sensitization may be an important common chronic tension-type headache (Bendtsen et al., 1996; Jensen denominator in the pain mechanisms of primary headaches, et al., 1998) . Furthermore, we demonstrated recently that although their basic pathophysiological mechanisms are NOS inhibition has an analgesic effect in chronic tension-type different. headache, probably due to reduction of central sensitization (Ashina et al., 1999) . Studies in rats and in humans have
